Lucid Diagnostics (LUCD) Expected to Announce Quarterly Earnings on Wednesday

Lucid Diagnostics (NASDAQ:LUCD) is projected to issue its Q2 2025 quarterly earnings data before the market opens on Wednesday, August 13th. Analysts expect the company to announce earnings of ($0.09) per share and revenue of $1.15 million for the quarter.

Lucid Diagnostics Price Performance

NASDAQ:LUCD opened at $1.00 on Tuesday. The business’s 50-day moving average is $1.14 and its two-hundred day moving average is $1.26. Lucid Diagnostics has a 12 month low of $0.73 and a 12 month high of $1.80. The firm has a market capitalization of $107.95 million, a PE ratio of -0.74 and a beta of 1.21.

Institutional Investors Weigh In On Lucid Diagnostics

A number of institutional investors have recently added to or reduced their stakes in the company. Geode Capital Management LLC lifted its position in Lucid Diagnostics by 420.3% in the second quarter. Geode Capital Management LLC now owns 1,577,369 shares of the company’s stock worth $1,814,000 after purchasing an additional 1,274,194 shares during the period. Goldman Sachs Group Inc. lifted its position in shares of Lucid Diagnostics by 35.7% during the 1st quarter. Goldman Sachs Group Inc. now owns 86,302 shares of the company’s stock valued at $129,000 after acquiring an additional 22,727 shares during the last quarter. Finally, Cubist Systematic Strategies LLC acquired a new stake in shares of Lucid Diagnostics during the 1st quarter valued at $39,000. 74.01% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on LUCD. Wall Street Zen lowered Lucid Diagnostics from a “hold” rating to a “sell” rating in a research report on Thursday, May 22nd. Ascendiant Capital Markets lifted their target price on Lucid Diagnostics from $7.50 to $7.75 and gave the stock a “buy” rating in a research report on Friday, June 6th. Needham & Company LLC reaffirmed a “buy” rating and set a $3.00 target price on shares of Lucid Diagnostics in a research report on Wednesday, July 16th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and set a $2.00 target price on shares of Lucid Diagnostics in a research report on Thursday, May 15th. One research analyst has rated the stock with a sell rating, four have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, Lucid Diagnostics currently has a consensus rating of “Moderate Buy” and a consensus price target of $3.55.

Lucid Diagnostics Company Profile

Lucid Diagnostics Inc operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma.